BACKGROUND: Different regulators or effectors of the metastatic cascade can be of prognostic and/or predictive significance. Cathepsin-D and nm23 operate at different levels of the metastatic process and have not yet been analyzed in combination in ovarian cancer. PATIENTS AND METHODS: The prevalence of cathepsin-D and nm23 expression was studied with immunohistochemistry in a cohort of 185 previously untreated cases of FIGO stage III ovarian cancer. Correlations with known prognostic factors were examined, and both uni- and multivariate survival analyses were performed. RESULTS: Epithelial cell cathepsin-D expression was found in 58% of cases, stromal cell cathepsin-D expression in 20%, and nm23 expression in 72%. Epithelial cell cathepsin-D expression was positively correlated with better differentiation of the tumor tissue (P = 0.034). No correlation was found between epithelial and stromal cell cathepsin-D expression, but a striking degree of positive correlation was demonstrated between epithelial cell cathepsin-D and nm23 expression (P = 0.005). None of the factors studied was of any value in predicting the response to platinum and anthracyclin combination chemotherapy, as assessed by second look laparotomy. In univariate analysis age, FIGO substage, histological type, differentiation grade, ascites, residual disease and epithelial cathepsin-D were associated with corrected survival. Neither stromal cell cathepsin-D, nor nm23 expression were of prognostic significance. However, in multivariate analysis the combination of epithelial and stromal cell cathepsin-D expression (P = 0.030), residual disease (P = 0.002) and differentiation grade (P = 0.007) were the only remaining independent prognostic factors in this patient group. CONCLUSIONS: Our results support a favourable prognostic significance of cathepsin-D expression in advanced ovarian cancer, but underscore the importance of considering both epithelial and stromal cell expression. We could not confirm the prognostic significance of nm23 expression in the present cohort of advanced ovarian cancer patients.
BACKGROUND: Different regulators or effectors of the metastatic cascade can be of prognostic and/or predictive significance. Cathepsin-D and nm23 operate at different levels of the metastatic process and have not yet been analyzed in combination in ovarian cancer. PATIENTS AND METHODS: The prevalence of cathepsin-D and nm23 expression was studied with immunohistochemistry in a cohort of 185 previously untreated cases of FIGO stage III ovarian cancer. Correlations with known prognostic factors were examined, and both uni- and multivariate survival analyses were performed. RESULTS: Epithelial cell cathepsin-D expression was found in 58% of cases, stromal cell cathepsin-D expression in 20%, and nm23 expression in 72%. Epithelial cell cathepsin-D expression was positively correlated with better differentiation of the tumor tissue (P = 0.034). No correlation was found between epithelial and stromal cell cathepsin-D expression, but a striking degree of positive correlation was demonstrated between epithelial cell cathepsin-D and nm23 expression (P = 0.005). None of the factors studied was of any value in predicting the response to platinum and anthracyclin combination chemotherapy, as assessed by second look laparotomy. In univariate analysis age, FIGO substage, histological type, differentiation grade, ascites, residual disease and epithelial cathepsin-D were associated with corrected survival. Neither stromal cell cathepsin-D, nor nm23 expression were of prognostic significance. However, in multivariate analysis the combination of epithelial and stromal cell cathepsin-D expression (P = 0.030), residual disease (P = 0.002) and differentiation grade (P = 0.007) were the only remaining independent prognostic factors in this patient group. CONCLUSIONS: Our results support a favourable prognostic significance of cathepsin-D expression in advanced ovarian cancer, but underscore the importance of considering both epithelial and stromal cell expression. We could not confirm the prognostic significance of nm23 expression in the present cohort of advanced ovarian cancerpatients.
Authors: M Ikeguchi; T Sakatani; T Ueta; K Fukuda; S Oka; K Hisamitsu; K Yamaguchi; S Tsujitani; N Kaibara Journal: J Clin Pathol Date: 2002-02 Impact factor: 3.411
Authors: S Kapitanović; T Cacev; M Berković; M Popović-Hadzija; S Radosević; S Seiwerth; S Spaventi; K Pavelić; R Spaventi Journal: J Clin Pathol Date: 2004-12 Impact factor: 3.411
Authors: Harvey H Hensley; Navid A Roder; Shane W O'Brien; Laura E Bickel; Fang Xiao; Sam Litwin; Denise C Connolly Journal: Neoplasia Date: 2012-06 Impact factor: 5.715
Authors: Florian Finkernagel; Silke Reinartz; Maximiliane Schuldner; Alexandra Malz; Julia M Jansen; Uwe Wagner; Thomas Worzfeld; Johannes Graumann; Elke Pogge von Strandmann; Rolf Müller Journal: Theranostics Date: 2019-08-22 Impact factor: 11.556
Authors: Boleslaw K Winiarski; Nichola Cope; Mary Alexander; Luke C Pilling; Sophie Warren; Nigel Acheson; Nicholas J Gutowski; Jacqueline L Whatmore Journal: Transl Oncol Date: 2014-03-04 Impact factor: 4.243